HUMAN ERYTHROID-POTENTIATING ACTIVITY
人红细胞增强活性
基本信息
- 批准号:3087366
- 负责人:
- 金额:$ 7.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-08-01 至 1991-07-31
- 项目状态:已结题
- 来源:
- 关键词:affinity chromatography antibody receptor binding proteins complementary DNA erythroid stem cell erythropoiesis gene expression genetic library genetic manipulation genetic transcription hematopoietic growth factor hormone receptor human tissue laboratory rabbit messenger RNA molecular cloning monoclonal antibody myelogenous leukemia myeloproliferative neoplasm neoplastic cell protein sequence radioimmunoassay tissue /cell culture
项目摘要
Hematopoiesis is tightly regulated by a series of hormonal factors that
stimulate the proliferation and differentiation of progenitor cells, as
well as modulate the functional activity of mature effector cells. Human
erythroid-potentiating activity (EPA) is a recently purified and
molecularly cloned growth factor which stimulates the growth of erythroid
precursors. The precise physiological role of EPA in the regulation of
hematopoiesis is unknown.
The proposed studies are designed to investigate the mechanisms of action
of EPA on normal and neoplastic cells through characterization at the
molecular level of the interaction of EPA with its receptor protein.
Target cells bearing receptors for EPA as determined by binding of labeled
125I-EPA will be used as a source for purifying the EPA receptor and
generating receptor antisera. Molecular clones encoding the EPA receptor
will be obtained and used to determine the structure and sequence of the
receptor protein and to examine its genomic organization in DNA. The cDNA
clones will then be used to study the regulation and expression of the EPA
receptor in normal and neoplastic cells.
I propose to comprehensively analyze the EPA receptor on normal human
peripheral blood and bone marrow cells, various human cell lines, and fresh
neoplastic cells. Receptor numbers, binding affinity, and molecular
properties of the receptor protein will be studied. Thus, significant
differences may be seen in the quantitative or qualitative characteristics
of the EPA receptor protein in normal and neoplastic cells which are
important in the maintenance of the normal and transformed malignant
state. Of particular interest is the possibility of tumor promoting
activities or translocations or amplifications of the EPA receptor gene in
specific neoplasias, in view of the association of some receptor proteins
with oncogenes.
Overall, these studies should yield new and important information on the in
vivo regulation by EPA of hematopoiesis and its role in the pathophysiology
of various disease states. Information gained from these studies should
contribute to our basic understanding of the interactions of hematopoietic
growth factors and their target cells. On a larger scale, this information
should expand our current fundamental knowledge of hematopoietic cell
growth and the interaction of growth factors and their receptors in normal
and malignant states.
造血受到一系列激素因素的严格调节,
刺激祖细胞的增殖和分化,
以及调节成熟效应细胞的功能活性。 人类
红细胞增强活性 (EPA) 是一种最近纯化和
刺激红细胞生长的分子克隆生长因子
前体。 EPA 在调节中的精确生理作用
造血作用未知。
拟议的研究旨在调查作用机制
通过表征 EPA 对正常细胞和肿瘤细胞的作用
EPA与其受体蛋白相互作用的分子水平。
带有 EPA 受体的靶细胞通过标记的结合来确定
125I-EPA将用作纯化EPA受体的来源和
产生受体抗血清。 编码EPA受体的分子克隆
将获得并用于确定结构和序列
受体蛋白并检查其在 DNA 中的基因组组织。 cDNA
然后克隆将用于研究 EPA 的调控和表达
正常细胞和肿瘤细胞中的受体。
我建议全面分析正常人体的EPA受体
外周血和骨髓细胞、各种人类细胞系和新鲜
肿瘤细胞。 受体数量、结合亲和力和分子
将研究受体蛋白的特性。 因此,显着
差异可能体现在数量或质量特征上
正常细胞和肿瘤细胞中的 EPA 受体蛋白
对于维持正常和转化的恶性细胞很重要
状态。 特别令人感兴趣的是促进肿瘤生长的可能性
EPA受体基因的活性或易位或扩增
鉴于某些受体蛋白的关联,特定肿瘤
与癌基因。
总体而言,这些研究应该会产生有关内部的新的重要信息。
EPA对造血的体内调节及其在病理生理学中的作用
各种疾病状态。 从这些研究中获得的信息应该
有助于我们对造血相互作用的基本理解
生长因子及其靶细胞。 从更大的范围来看,这些信息
应该扩展我们目前对造血细胞的基础知识
正常情况下的生长以及生长因子及其受体的相互作用
和恶性状态。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Belinda Rene Avalos其他文献
Belinda Rene Avalos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Belinda Rene Avalos', 18)}}的其他基金
LOSS OF NEGATIVE SIGNALING BY THE G-CSFR IN AML
AML 中 G-CSFR 负信号丢失
- 批准号:
6514159 - 财政年份:1999
- 资助金额:
$ 7.33万 - 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE G-CSFR IN AML
AML 中 G-CSFR 负信号丢失
- 批准号:
6174121 - 财政年份:1999
- 资助金额:
$ 7.33万 - 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE G-CSFR IN AML
AML 中 G-CSFR 负信号丢失
- 批准号:
6377439 - 财政年份:1999
- 资助金额:
$ 7.33万 - 项目类别:
LOSS OF NEGATIVE SIGNALING BY THE GCSFR IN AML
AML 中 GCSFR 负信号丢失
- 批准号:
2899455 - 财政年份:1999
- 资助金额:
$ 7.33万 - 项目类别:
G-CSFR MUTATIONS--A NOVEL MECHANISM OF LEUKEMOGENESIS
G-CSFR突变——白血病发生的新机制
- 批准号:
2382809 - 财政年份:1997
- 资助金额:
$ 7.33万 - 项目类别:
G-CSFR MUTATIONS--A NOVEL MECHANISM OF LEUKEMOGENESIS
G-CSFR突变——白血病发生的新机制
- 批准号:
2748953 - 财政年份:1997
- 资助金额:
$ 7.33万 - 项目类别:
相似海外基金
Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
- 批准号:
23H02361 - 财政年份:2023
- 资助金额:
$ 7.33万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : GNT1124162 - 财政年份:2017
- 资助金额:
$ 7.33万 - 项目类别:
Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : 1124162 - 财政年份:2017
- 资助金额:
$ 7.33万 - 项目类别:
Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9300976 - 财政年份:2015
- 资助金额:
$ 7.33万 - 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9920805 - 财政年份:2015
- 资助金额:
$ 7.33万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8900121 - 财政年份:2012
- 资助金额:
$ 7.33万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8225814 - 财政年份:2012
- 资助金额:
$ 7.33万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8699511 - 财政年份:2012
- 资助金额:
$ 7.33万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8525355 - 财政年份:2012
- 资助金额:
$ 7.33万 - 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
- 批准号:
9115537 - 财政年份:1991
- 资助金额:
$ 7.33万 - 项目类别:
Standard Grant














{{item.name}}会员




